» Articles » PMID: 23318480

Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients with Inflammatory Bowel Disease

Abstract

Objectives: The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these drugs in this situation is limited. Our aim is to assess the safety of thiopurines and anti-TNF-α drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy.

Methods: Retrospective, multicenter study in IBD patients. Pregnancies were classified according to the therapeutic regimens during pregnancy or during the 3 months before the conception: non-exposed group, pregnancies exposed to thiopurines alone (group A), and pregnancies exposed to anti-TNF-α drugs (group B). An unfavorable Global Pregnancy Outcome (GPO) was considered if pregnancy developed with obstetric complications in the mother and in the newborn.

Results: A total of 187 pregnancies in the group A, 66 pregnancies in the group B, and 318 pregnancies in the non-exposed group were included. The rate of unfavorable GPO was different among the three groups (31.8% in non-exposed group, 21.9% in group A, and 34.8% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). The rate of pregnancy complications was similar among the three groups (27.7% in non-exposed, 20.9% in group A, and 30.3% in group B). The rate of neonatal complications was different among the three groups (23.3% in non-exposed group, 13.9% in group A, and 21.2% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). In the multivariate analysis, the treatment with thiopurines (odds ratio = 0.6; 95% confidence interval = 0.4-0.9, P = 0.02) was the only predictor of favorable GPO, whereas maternal age >35 years at conception was the only predictor of unfavorable GPO. The treatment with anti-TNF-α drugs was not associated with an unfavorable GPO.

Conclusion: The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn.

Citing Articles

Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.

Yen H, Wu J, Wang H, Chang T, Chang C, Chang C Intest Res. 2024; 22(3):213-249.

PMID: 39099217 PMC: 11309818. DOI: 10.5217/ir.2023.00050.


Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review.

Huang W, Zhang X, Zhang L, Dai X, Chen H, Xie Q BMC Pregnancy Childbirth. 2024; 24(1):251.

PMID: 38589784 PMC: 11000337. DOI: 10.1186/s12884-024-06443-w.


The Fundamentals of Inflammatory Bowel Disease Management in Pregnancy: A Practical Review for the Gastroenterologist.

Squirell E, Meade S, Leung Y J Can Assoc Gastroenterol. 2024; 7(1):121-131.

PMID: 38314178 PMC: 10836983. DOI: 10.1093/jcag/gwad056.


Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy.

Azzam N, AlMutairdi A, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O Saudi J Gastroenterol. 2023; .

PMID: 38099556 PMC: 11379253. DOI: 10.4103/sjg.sjg_318_23.


IBD and Motherhood: A Journey through Conception, Pregnancy and Beyond.

Caballero-Mateos A, Quesada-Caballero M, Canadas-De la Fuente G, Caballero-Vazquez A, Contreras-Chova F J Clin Med. 2023; 12(19).

PMID: 37834837 PMC: 10573266. DOI: 10.3390/jcm12196192.